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We recently described acidified citrate cysteine medium (ACCM), which supports host cell-free (axenic)
growth of Coxiella burnetii. After 6 days of incubation, greater than 3 logs of growth was achieved with the
avirulent Nine Mile phase II (NMII) strain. Here, we describe modified ACCM and culture conditions that
support improved growth of C. burnetii and their use in genetic transformation and pathogen isolation from
tissue samples. ACCM was modified by replacing fetal bovine serum with methyl--cyclodextrin to generate
ACCM-2. Cultivation of NMII in ACCM-2 with moderate shaking and in 2.5% oxygen yielded 4 to 5 logs of
growth over 7 days. Similar growth was achieved with the virulent Nine Mile phase I and G isolates of C.
burnetii. Colonies that developed after 6 days of growth in ACCM-2 agarose were approximately 0.5 mm in
diameter, roughly 5-fold larger than those formed in ACCM agarose. By electron microscopy, colonies con-
sisted primarily of the C. burnetii small cell variant morphological form. NMII was successfully cultured in
ACCM-2 when medium was inoculated with as little as 10 genome equivalents contained in tissue homogenates
from infected SCID mice. A completely axenic C. burnetii genetic transformation system was developed using
ACCM-2 that allowed isolation of transformants in about 2 1/2 weeks. Transformation experiments demon-
strated clonal populations in colonies and a transformation frequency of approximately 5  105. Cultivation
in ACCM-2 will accelerate development of C. burnetii genetic tools and provide a sensitive means of primary
isolation of the pathogen from Q fever patients.
Coxiella burnetii is a wide-ranging zoonotic pathogen that
causes a debilitating influenza-like illness in humans called Q
fever (20). Following infection of a eukaryotic host cell, this
intracellular bacterium replicates exclusively within a phago-
lysosome-like parasitophorous vacuole (PV) (16). C. burnetii
directs development of the PV (15, 24) and manipulates other
host cell functions such as apoptotic signaling (18, 29). The
mechanisms by which C. burnetii modifies the host cell and
causes disease are largely unknown. Indeed, lipopolysaccha-
ride is the only defined virulence factor of C. burnetii with the
full-length molecule of phase I bacteria required for full viru-
lence (21).
The obligate intracellular nature of C. burnetii has severely
impeded development of genetic tools for virulence factor dis-
covery. Beare et al. (3) recently genetically transformed C.
burnetii to chloramphenicol resistance and mCherry red fluo-
rescent protein expression using the mariner-based Himar1
transposon. However, a significant limitation of the procedure
is the 8 to 12 weeks required for expansion and clonal isolation
of individual transposon mutants using cell culture-based prop-
agation of C. burnetii. Moreover, the micromanipulation
method used for harvesting clonal C. burnetii from an individ-
ual PV is technically challenging.
The recent description of a method for axenic (host cell-
free) propagation of C. burnetii is a significant technological
advance that will facilitate biochemical and genetic studies of
the pathogen (22). A growth medium called acidified citrate
cysteine medium (ACCM) was developed that supports
roughly 3 logs (log10) of growth of C. burnetii over 6 days in a
microaerobic environment. Minute (approximately 0.1 mm in
diameter) colonies also develop over the same time frame in
semisolid ACCM agarose. In the current study, we describe a
modified version of ACCM called ACCM-2 that supports im-
proved growth of C. burnetii in liquid medium and as colonies
in agarose plates. Colonies contained clonal populations,
thereby facilitating development of a fully axenic system for C.
burnetii genetic transformation that substantially reduces the
time of transformant isolation. ACCM-2 cultures were also
successfully started with infected animal tissue homogenates
containing small numbers of C. burnetii, thereby providing a
potential means of obtaining clinical isolates from Q fever
patients.
MATERIALS AND METHODS
C. burnetii isolates and host cell-based propagation. C. burnetii Nine Mile
phase II, clone 4 (NMII; RSA439), and low-passage-number stocks of Nine Mile
phase I (NMI; RSA493) and G (Q212) isolates were used in this study. Host
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cell-based growth of C. burnetii was accomplished using African green monkey
kidney (Vero) fibroblasts (CCL-81; American Type Culture Collection) grown in
RPMI medium (Invitrogen, Carlsbad, CA) supplemented with 2% fetal bovine
serum (FBS) at 37°C in a 5% CO2 atmosphere. Bacteria were purified from host
cells using differential centrifugation as previously described (10) and stored at
80°C.
Axenic cultivation. A modified form of ACCM (22) called ACCM-2, in which
1% FBS is replaced with 1 mg/ml methyl--cyclodextrin (M-CD), was devel-
oped. C. burnetii was cultivated in T-75 cell culture flasks or 0.2-m-pore-size-
filter-capped 125-ml Erlenmeyer flasks containing 20 ml of medium, T-25 flasks
containing 5 ml of medium, or 6-well tissue culture plates containing 3 ml of
medium per well. Cultures were incubated at 37°C in a 2.5% O2 and 5% CO2
environment using a CO-170 incubator (New Brunswick Scientific, NJ). Oxygen
was displaced by nitrogen gas. Where indicated, Erlenmeyer flasks were shaken
at 75 rpm. C. burnetii replication was measured by optical density at 600 nm
(OD600) or quantitative PCR (Q-PCR) of genome equivalents (GE) using a dotA
probe as previously described (22).
C. burnetii colonies were established using a modified soft agarose overlay
method in which bacteria are grown in the top medium layer. A 0.25% ACCM-2
agarose base in 100- by 20-mm petri dishes was created by mixing 10 ml of
filter-sterilized 2 ACCM-2 with 10 ml of 0.5% (wt/vol in water) melted Ultra-
Pure agarose (Invitrogen). The bacterial inoculum was mixed with 2.5 ml of 0.1%
melted ACCM-2 agarose equilibrated to 37°C, which was prepared by mixing
together 1.25 ml of 2 ACCM-2, 0.75 ml of water, and 0.5 ml of 0.5% melted
agarose. This solution was poured on top of the solidified ACCM-2 agarose base.
Plates were refrigerated (4°C) for 30 min to aid solidification of the top agarose
and then placed in a laminar airflow biosafety cabinet with lids ajar for 20 min to
remove condensation. Plates were incubated for 6 days as described above for
ACCM-2 to allow colony development.
Electron microscopy of C. burnetii propagated as colonies. NMII grown as
colonies was obtained from ACCM-2 agarose plates incubated for 6 days. The
top agarose was removed using a cell scraper, and then the agarose base was
rinsed with 1 ml phosphate-buffered saline (PBS; 10 mM Na2HPO4, 10 mM
NaH2PO4, 150 mM NaCl, pH 7.8). The agarose and rinse samples were com-
bined in 2-ml microcentrifuge tubes, and then samples were disrupted by re-
peated pipetting to release bacteria embedded in agarose. Samples were centri-
fuged at 2,000  g for 5 min to pellet the agarose, and then supernatants were
transferred to clean 1.5-ml microcentrifuge tubes that were centrifuged at
20,000  g for 15 min to pellet C. burnetii. Bacteria were fixed for 2 h in 2.5%
glutaraldehyde (vol/vol) with 0.05 M sucrose in 0.1 M sodium cacodylate buffer.
Subsequent postfixation steps were performed with microwave irradiation in
cycles of 2 min on, 2 min off, 2 min on at 250 W under vacuum (Pelco 3451; Ted
Pella, Redding, CA). Samples were then incubated in 0.5% osmium tetroxide–
0.8% potassium ferricyanide in 0.1 M sodium cacodylate, followed by 1% tannic
acid in distilled water and finally 1% uranyl acetate in distilled water. Samples
were dehydrated in a graded ethanol series for 1 min under vacuum and then
infiltrated with Spurr’s resin by incubation in graded Spurr’s solutions (1:3, 1:1,
3:1 [Spurr’s:ethanol]) using a microwave processor at 5-min cycles before em-
bedding in Spurr’s resin. Sections (80 nm) were cut using a Leica UC6 ultr-
amicrotome (Leica Microsystems, Vienna, Austria) and stained with 1% uranyl
acetate and Reynolds lead citrate. Samples were examined with a Hitachi H-7500
electron microscope (Hitachi, Pleasanton, CA), and images were captured with
a Hamamatsu XR-100 digital camera system (AMT, Danvers, MA).
Establishment of antibiotic MICs. The MICs of chloramphenicol and kana-
mycin required to inhibit NMII growth in ACCM-2 were determined by
incubating organisms in medium containing 0.375, 0.75, 1.5, or 3 g/ml of
chloramphenicol or 125, 250, 375, or 500 g/ml of kanamycin. Chloramphen-
icol and kanamycin were dissolved in ethanol and water, respectively. Sol-
vents had no effect on C. burnetii growth when tested at the highest concen-
trations used in the assay. Growth in liquid ACCM-2 was measured by
determining the OD600s of cultures grown in 3 ml of medium in a 6-well tissue
culture plate. MICs were also established for NMII growth in ACCM-2
agarose using a CFU assay.
Colony genotyping. ACCM-2 agarose was plated with equal numbers of wild-
type NMII and an NMII transformant termed NMII-MC1 that contains a
Himar1 transposon insertion between CBU0316 and CBU0317 (3, 4). Fourteen
random colonies were picked from plates after 6 days of growth. A Zeiss Stemi
2000 stereo microscope was used to help visualize colonies averaging 0.5 mm in
diameter. Colony locations were marked, and then individual colonies were
extracted from the agarose overlay using a P-1000 pipette tip. To facilitate
removal of colonies, the pipette tip opening was enlarged to approximately 5 mm
in diameter by cutting the tip end. These modified tips were autoclaved prior to
use. Each agarose plug was added to 1.0 ml of ACCM-2 in a sterile 1.5-ml
microcentrifuge tube, and organisms were released from the agarose by repeated
pipetting. The mixture was then added to 2 ml of sterile ACCM-2 (3 ml total) in
6-well plates that were incubated for 6 days to expand colony populations.
Cultures were genotyped for the presence of NMII or NMII-MC1 by using PCR.
Two microliters of culture medium was added directly to a PCR mix that con-
tained primers specific to CBU0316 (CBU0316-F, forward primer) and
CBU0317 (CBU0317-R, reverse primer) (Table 1). PCRs were conducted using
AccuPrime Taq DNA polymerase (Invitrogen), and reaction products were an-
alyzed by gel electrophoresis using a 0.8% agarose gel. Products of 1.6 and 4.8 kb
are expected from amplification of NMII and NMII-MC1 genomic DNA, re-
spectively.
Transformation of NMII. The plasmids pJB-CAT and pJB-KAN (Fig. 1),
conferring resistance to chloramphenicol and kanamycin, respectively, were used
to transform NMII, and were constructed using pJB2581 as the backbone (2).
The cyaA gene of pJB2581 was first replaced with the mCherry gene, which was
amplified by PCR from p1898-Tn (3) using primers MCforpJB2581-F and
MCforpJB2581-R (Table 1), and cloned into plasmid digested with EcoRI and
BamHI. The chloramphenicol acetyltransferase (CAT) gene was amplified from
pJB2581 using the primers CAT-P1169F and CAT-pJB2581-HindIIIrecR, and
the kanamycin resistance gene (KAN) was amplified from pCR2.1-topo using the
primers KAN-P1169F and KAN-pJB2581-HindIIIrecR. The CBU1169 promoter
FIG. 1. Composite map of pJB-CAT and pJB-KAN. Plasmids con-
tain a RSF1010 origin of replication and a chloramphenicol or kana-
mycin resistance gene under the control of the C. burnetii CBU1169
promoter.
























(P1169) was amplified from C. burnetii genomic DNA using the primers P1169-
pJB2581-Ab-HindIIIrecF and P1169-R. The CAT and KAN genes were placed
downstream from P1169 to create P1169-CAT and P1169-KAN cassettes using
overlapping PCR and the primers P1169-pJB2581-Ab-HindIIIrecF and CAT-
pJB2581-HindIIIrecR or KAN-pJB2581-HindIIIrecR, respectively. P1169-CAT
and P1169-KAN cassettes were cloned into HindIII-digested pJB2581::mCherry
using the In-fusion kit (BD Clontech, Mountain View, CA) to create pJB-CAT
and pJB-KAN, respectively. PCR was conducted with AccuPrime Pfx polymerase
(Invitrogen) and primers from Integrated DNA Technologies (Coralville, IA).
Transformation experiments used NMII cultured for 6 days in ACCM-2.
Cultures were grown with shaking in Erlenmeyer flasks. Bacteria were pelleted
by centrifugation for 15 min at 16,000  g, washed in 10% glycerol, pelleted
again, and then suspended in 10% glycerol at a cell density of approximately 4 
109 GE/ml. Organisms were kept on ice until electroporation. Fifty microliters of
C. burnetii suspension (2  108 GE) was mixed with 10 g of pJB-CAT or
pJB-KAN and placed in a 0.1-cm electroporation cuvette (precooled on ice).
Cells were electroporated at 18 kV, 500 , and 25 F for 7 to 13 ms, which
results in approximately 50% killing (unpublished observations). Immediately
following electroporation, 950 l of RPMI cell culture medium was added to the
cuvette and the sample was mixed, and then 200 l was added to 3 ml of
ACCM-2 in a 6-well plate. Cultures were incubated overnight, and then kana-
mycin (final concentration of 375 g/ml) or chloramphenicol (final concentration
of 3 g/ml) was added to the medium for transformant selection. C. burnetii
transformants were cultured for a total of 4 days; then, 100 l of the culture was
plated on antibiotic-containing ACCM-2 agarose.
Genes conferring resistance to chloramphenicol, kanamycin, or ampicillin are
approved for C. burnetii genetic transformation by the Rocky Mountain Labo-
ratories Institutional Biosafety Committee and the Centers for Disease Control
and Prevention Select Agents Program.
SCID mice infections. Six-week-old SCID mice (NOD.CB17-Prkdcscid/J) were
purchased from Jackson Laboratory. Three mice per group were challenged
intratracheally or intraperitoneally with 106 GE of ACCM-2-grown NMII. At 7
days postinfection, lungs, liver, and spleen were aseptically harvested and stored
at 80°C. At the time of processing, whole organs were disrupted by gentle
mechanical homogenization in 5 ml of ACCM-2. To quantify bacterial load by
Q-PCR, 50 l of tissue homogenate was processed using the High-Pure PCR
template kit (Roche) and NMII GE were determined using primers specific for
the C. burnetii com1 gene as previously described (6). Culture positivity was
determined by inoculating 5 ml of ACCM-2 in T-25 flasks with 50 l of 100-
fold-diluted tissue homogenates containing known amounts of NMII GE. After
a 7-day incubation, 1 ml of each ACCM-2 culture was centrifuged at 15,000  g
for 20 min to pellet NMII. The bacterial pellet was suspended in 100 l of
sucrose phosphate buffer (PBS containing 250 mM sucrose), and 25 l was
processed for Q-PCR as described above. Animal experiments were performed
according to protocol number AUP2009-20 approved by the University Animal
Care Committee of Texas A&M University.
RESULTS
NMII growth is improved in ACCM-2. ACCM contains FBS
and supports roughly 3 logs of NMII growth over a 6-day
incubation without shaking (22). We found that by replacing
FBS with 1.0 mg/ml M-CD to generate ACCM-2, and by
slowly shaking the cultures (75 rpm), growth yield of NMII was
improved. NMII cultures were initiated with approximately 103
organisms/ml, and the OD600 and GE were measured over a
7-day incubation. Cultures in ACCM without shaking and in
ACCM-2 with shaking showed OD600 increases from 0 to
0.160  0.004 and 0.587  0.003, respectively. Q-PCR showed
GE increases of 2.9  0.075 and 4.4  0.042 logs in ACCM
without shaking and in ACCM-2 with shaking, respectively
(Fig. 2A). The log phase (1 to 3 days postinoculation) gener-
ation time of NMII in ACCM-2 was 4.7 h, 4.4 h less than that
observed in ACCM (22). Shaking of ACCM moderately im-
proved NMII growth but not to the level of growth in shaken
ACCM-2 (data not shown).
ACCM-2 supports growth of virulent C. burnetii. The avir-
ulent NMII isolate was used to develop ACCM (22) and
ACCM-2 culture methods. To confirm that ACCM-2 supports
growth of virulent C. burnetii isolates, media were inoculated
with the NMI and G isolates (5) and their growth was assessed.
In ACCM-2, NMI and G exhibited growth yield equivalent to
that observed for NMII with 4.5  0.094 and 4.1  0.378 logs
of growth over 7 days, respectively (Fig. 2B).
Colony growth is improved in ACCM-2 agarose. NMII
forms minute (approximately 0.1-mm-diameter) colonies in
ACCM agarose (22). To test whether improved growth of
NMII in ACCM-2 correlated with larger colonies in ACCM-2
agarose, NMII was plated and colony size was assessed after a
6-day incubation. Colonies in ACCM-2 agarose were 5-fold
larger (approximately 0.5 mm in diameter) than those in
ACCM agarose (Fig. 3A and B). Colonies in ACCM-2 agarose
were primarily comprised of the small cell variant (SCV) form
of C. burnetii as assessed by size and characteristic condensed
chromatin (9) (Fig. 3C). Virulent NMI and G strains formed
colonies in ACCM-2 agarose similar in size to those formed by
NMII (data not shown).
FIG. 2. Cultivation of C. burnetii in ACCM-2. (A) Growth of NMII in ACCM-2 with shaking (solid line) and ACCM without shaking (dotted
line). (B) Growth of the virulent C. burnetii NMI (dotted line) and G (solid line) isolates in ACCM-2 with shaking. Growth was measured by
enumerating GE, and results are from three separate cultures  the standard error of the mean.












C. burnetii colonies in ACCM-2 agarose are clonal. The
plating efficiency of NMII in ACCM-2 agarose was 1 to 2 GE
per colony formed, suggesting that colonies develop from sin-
gle organisms. To confirm clonality, ACCM-2 agarose was
plated with equal numbers of wild-type NMII and a NMII
transformant termed NMII-MC1 that contains a Himar1 trans-
poson insertion between CBU0316 and CBU0317 conferring
mCherry expression and chloramphenicol resistance (3, 4).
NMII-MC1 and NMII have been previously shown to grow at
equal rates (4). Fourteen random colonies were picked from
plates after 6 days of growth, expanded in ACCM-2, and then
genotyped by PCR. Each colony contained either NMII or
NMII-MC1 but not both (Fig. 4), illustrating the clonality of C.
burnetii colonies in ACCM-2 agarose.
Culture in ACCM-2 accelerates C. burnetii genetic transfor-
mation. The host cell-based C. burnetii genetic transformation
protocol described by Beare et al. (3) requires 8 to 12 weeks for
clonal isolation of transformants. Therefore, we investigated
whether ACCM-2 culture methods could accelerate the pro-
cedure. The first step was to determine the MICs of chloram-
phenicol and kanamycin in ACCM-2. NMII was cultured
under different antibiotic concentrations, and growth was mea-
sured by OD600 in ACCM-2, or colony development in
ACCM-2 agarose, after a 6-day incubation. The MICs of chlor-
amphenicol and kanamycin in ACCM-2 were 1.5 g/ml and
375 g/ml, respectively. The MICs of chloramphenicol and
kanamycin in ACCM-2 agarose were 3.0 g/ml and 375 g/ml,
respectively.
We next optimized a procedure for isolating C. burnetii
transformants and established a transformation frequency. The
plasmids pJB-CAT and pJB-KAN, conferring chloramphenicol
and kanamycin resistance, respectively, were constructed for
these experiments (see Fig. 1 and Materials and Methods).
These plasmids contain an RSF1010 origin of replication that
can support autonomous replication of heterologous plasmid
DNA in C. burnetii (7). Following electroporation, optimal
recovery of antibiotic-resistant colonies in ACCM-2 agarose
was observed if organisms were plated after 4 days of recovery
in ACCM-2. Almost no colonies were observed prior to this
point. Based on colony counts, an estimated 8  104 pJB-CAT
and 4 104 pJB-KAN transformants were present in ACCM-2
before plating. Assuming that the 1  108 viable C. burnetii
transformants remaining after electroporation underwent
eight divisions during recovery in ACCM-2, we estimate a
transformation frequency of approximately 5  105. Thus,
genetic transformants can be recovered for analysis in as little
as 16 days using axenic culture: 4 days of transformant recovery
FIG. 3. Colony formation by C. burnetii in ACCM and ACCM-2
agarose. (A) Representative ACCM plate showing NMII colonies that
average approximately 0.1 mm in diameter. Scale bar, 10 mm. (B) Rep-
resentative ACCM-2 plate showing NMII colonies that average ap-
proximately 0.5 mm in diameter. Scale bar, 10 mm. (C) Electron
microscopy of colony-grown C. burnetii showing primarily the SCV
morphological form. Scale bar, 0.5 m.
FIG. 4. NMII colonies in ACCM-2 agarose are clonal. Equal num-
bers of NMII and NMII-MC1, which contains a Himar1 transposon
insertion between CBU0316 and CBU0317, were plated in ACCM-2
agarose. Fourteen random colonies were picked after 6 days of growth
and genotyped as described in Materials and Methods. Each colony
contained either NMII (1.6-kb band) or NMII-MC1 (4.8-kb band) but
not both, showing the clonality of C. burnetii colonies in ACCM-2
agarose.












in ACCM-2, 6 days of colony development in ACCM-2 aga-
rose, and 6 days of colony expansion in ACCM-2.
ACCM-2 supports growth of C. burnetii isolated from ani-
mal tissue. Cell culture-based methods of isolating virulent C.
burnetii from clinical samples have variable success rates (13,
27). Therefore, we tested whether ACCM-2 can be used to
isolate C. burnetii from animal tissue. As a model, NMII-
infected SCID mice were employed (1, 23, 25). Mice were
infected intratracheally or intraperitoneally, and lungs, liver,
and spleen were harvested at 7 days postinfection. Five ml of
ACCM-2 was inoculated with a 1:100 dilution of tissue homog-
enate, and growth over 7 days was measured by Q-PCR (Fig.
5). Based on the starting number of GE/ml, NMII burdens
were highest in tissues harvested from mice infected intraperi-
toneally. NMII was recovered by axenic cultivation from all
tissues, with GE increases of several logs observed for all
inocula. The method was highly sensitive, with several cultures
successfully started with fewer than 100 total C. burnetii GE. In
fact, one 5-ml culture was started with 10 GE contained in
diluted lung homogenate from a mouse infected intraperito-
neally (Fig. 5).
DISCUSSION
In the current study, we describe improved ACCM-based
culture methods and their use in a fully axenic system for C.
burnetii genetic transformation and isolation of the pathogen
from tissue. Culturing of C. burnetii in gently shaken ACCM-2,
containing M-CD instead of FBS, results in an approximately
1.5 log increase in bacterial yield compared to that obtained
when culturing in ACCM. Pathogen generation time in
ACCM-2 is reduced to 4.7 h, almost half of that observed in
ACCM. In addition, average colony size is increased by about
5-fold to a diameter of approximately 0.5 mm, greatly facili-
tating the isolation and characterization of clonal populations
of C. burnetii.
The use of ACCM-2 in C. burnetii genetic transformation
has several advantages over the previously described Vero cell
system of transformant propagation (3). First, the time re-
quired to isolate clonal populations of C. burnetii transfor-
mants is reduced from 2 to 3 months to as little as 16 days.
Second, axenic culture allows recovery of some C. burnetii
transformants incapable of intracellular growth. Third, trans-
formation frequency can be estimated.
The substitution of M-CD for FBS in ACCM-2 improves
C. burnetii growth. Cyclodextrins can also replace FBS in
Helicobacter pylori culture medium (19) and similarly improves
growth of Bordetella pertussis (17). Improved growth may result
from M-CD sequestration of inhibitory metabolites, such as
certain fatty acids (11).
C. burnetii colony size increases as the agarose percentage
decreases (A. Omsland and R. A. Heinzen, unpublished ob-
servations). By mixing the bacterial inoculum with a low-den-
sity (0.1%) ACCM-2 agarose top medium, colonies develop to
approximately 0.5 mm in diameter. By applying the overlay
agarose containing C. burnetii to a higher-density (0.25%) aga-
rose base, a stable matrix is achieved that allows handling of
plates with minimal disruption of the overlay medium. We are
uncertain why C. burnetii colonies are so small, but potential
explanations include the presence of a toxic component in the
agarose or the release by C. burnetii of a metabolite that
changes the microenvironment, such as a basic compound that
neutralizes local pH, thereby inhibiting C. burnetii metabolism
(14). Alternatively, the observation that colonies are primarily
comprised of SCVs, a stationary-phase cell form, suggests that
the agarose immediately adjacent to colonies has been de-
pleted of nutrients. Despite the colonies’ small size, C. burnetii
displays a nearly one-genome-per-colony plating efficiency in
ACCM-2 agarose, indicating that a conventional CFU assay
can be used to accurately assess C. burnetii viability.
Approximately 6 GE of avirulent C. burnetii in phase II is
required to produce one infectious focus-forming unit (FFU)
in Vero cells (8). In contrast, roughly 300 GE of virulent C.
burnetii in phase I is required to produce a single FFU (R. A.
Heinzen, unpublished data). This behavior is attributed to the
hydrophilic nature of phase I C. burnetii, conferred by O-anti-
gen sugars, which nonspecifically inhibit host cell plasma mem-
brane interactions relative to hydrophobic phase II organisms,
with a truncated lipopolysaccharide (LPS) (28). The low infec-
tivity of virulent phase I C. burnetii for cell culture likely lowers
the success rate of primary isolation using tissue culture sys-
tems. Here, we demonstrate that mouse tissue samples con-
taining as little as 10 NMII GE can initiate cultures in
ACCM-2. Thus, axenic culture in ACCM-2 should provide a
sensitive method for isolating virulent C. burnetii in clinical
samples. Indeed, recent large Q fever outbreaks in Europe (12,
26) reinforce the need for such an enhanced surveillance and
diagnostic tool.
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